InnoCare Pharma Gains NMPA Approval for Minjuvi in China

An announcement from InnoCare Pharma Ltd. ( (HK:9969) ) is now available.

InnoCare Pharma Ltd. announced that the National Medical Products Administration (NMPA) in China has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. This approval marks the first CD19 antibody approved for this indication in China, potentially enhancing InnoCare’s market presence in the region. The approval is expected to have a significant impact on the company’s operations and industry positioning, given the high incidence of DLBCL in China, which accounts for 45.8% of all non-Hodgkin lymphoma cases in the country.

The most recent analyst rating on (HK:9969) stock is a Buy with a HK$11.76 price target. To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock, see the HK:9969 Stock Forecast page.

More about InnoCare Pharma Ltd.

InnoCare Pharma Ltd. is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies for the treatment of cancer and autoimmune diseases. The company operates primarily in the Greater China region, with a significant focus on hematology and oncology.

Average Trading Volume: 13,579,270

Technical Sentiment Signal: Buy

Current Market Cap: HK$15.26B

See more data about 9969 stock on TipRanks’ Stock Analysis page.